Top Stocks
Stock Comparison
About Us
Working with TipRanks
Follow Us
Protagonist Therapeutics (PTGX)
NASDAQ:PTGX
Protagonist Therapeutics Stock Analysis & Ratings
PTGX Stock Chart & Stats
Day’s Range$7.69 - $8.04
52-Week Range$7.49 - $50.54
Previous Close$7.85
Volume363.12K
Average Volume (3M)1.04M
Market Cap$384.87M
P/E Ratio-3.0
Beta2.58
Next EarningsAug 09, 2022
EPS Forecast-$0.94
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price Target$45.00
Smart Score4
EPS (TTM)-2.59
Protagonist Therapeutics News
P/E Ratio Range
The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PTGX FAQ
What was Protagonist Therapeutics’s price range in the past 12 months?
Protagonist Therapeutics lowest stock price was $7.49 and its highest was $50.54 in the past 12 months.
What is Protagonist Therapeutics’s market cap?
Protagonist Therapeutics’s market cap is $384.87M.
What is Protagonist Therapeutics’s price target?
The average price target for Protagonist Therapeutics is $45.00. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $50.00 ,the lowest forecast is $40.00. The average price target represents 468.90% Increase from the current price of $7.91.
The highest analyst price target is $50.00 ,the lowest forecast is $40.00. The average price target represents 468.90% Increase from the current price of $7.91.
What do analysts say about Protagonist Therapeutics?
Protagonist Therapeutics’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
When is Protagonist Therapeutics’s upcoming earnings report date?
Protagonist Therapeutics’s upcoming earnings report date is Aug 09, 2022 which is in 82 days.
How were Protagonist Therapeutics’s earnings last quarter?
Protagonist Therapeutics released its earnings results on May 04, 2022. The company reported -$0.43 earnings per share for the quarter, beating the consensus estimate of -$0.54 by $0.11.
Is Protagonist Therapeutics overvalued?
According to Wall Street analysts Protagonist Therapeutics’s price is currently Undervalued.
Does Protagonist Therapeutics pay dividends?
Protagonist Therapeutics does not currently pay dividends.
What is Protagonist Therapeutics’s EPS estimate?
Protagonist Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Protagonist Therapeutics have?
Protagonist Therapeutics has 48,660,000 shares outstanding.
What happened to Protagonist Therapeutics’s price movement after its last earnings report?
Protagonist Therapeutics reported an EPS of -$0.43 in its last earnings report, beating expectations of -$0.54. Following the earnings report the stock price went down -0.204%.
Which hedge fund is a major shareholder of Protagonist Therapeutics?
Among the largest hedge funds holding Protagonist Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds Protagonist Therapeutics’s shares valued at 27M.
---
Protagonist Therapeutics Stock Analysis
Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Price Target
$45.00
Strong Buy▲(468.90% Upside)
Analyst Forecast
Strong Buy
Average Price Target: $45.00
Blogger Sentiment
Bullish
PTGX Sentiment 100% Sector Average 71%
Hedge Fund Holdings
▼ Decreased
By 2.0M Shares Last Quarter.
Insider Transactions
▲ Bought Shares
Worth $233.8K over the Last 3 Months
Retail Investors
Very Negative
Last 7 Days ▼ 0.6% Last 30 Days ▼ 2.4%
News Sentiment
Neutral
Bullish 50% Bearish 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.15%
12-Months-Change
Fundamentals
Return on Equity
-43.66%
Trailing 12-Months
Asset Growth
16.85%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Protagonist Therapeutics
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. The firm's initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn's disease, respectively. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
---
Company
Price & Change
Follow
Novartis
―
Seres Therapeutics
―
Nektar Therapeutics
―
Gilead Sciences
―
---